Sep 3, 2025 ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
Aug 13, 2025 ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights